Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 7 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WHTC 1450 Holland· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Germany’s ITM raises $205M as radiopharma field booms
BioPharma Dive via Yahoo Finance· 22 hours agoBristol Myers spent $4.1 billion to buy RayzeBio; AstraZeneca paid $2 billion for Fusion...
How Messenger RNA Made The COVID Vaccines Possible
Science Friday· 2 hours agoThe following is an excerpt from The Catalyst: RNA and the Quest to Unlock Life’s Deepest Secrets by Thomas R. Cech. On January 10, 2020, Prof. Yong-Zhen Zhang of Fudan University in Shanghai ...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth outside of obesity, so a future win in that segment would just be the icing on the cake. 2. < ...
G42, an Emirati AI hopeful, has big plans
The Economist· 17 hours agoTHE MIDDLE EAST is something of a tech desert. One company trying to change this is G42, founded six years ago in the United Arab Emirates (UAE). More...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 3 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
